Zydus Lifesciences (ZYDUSLIFE) Q4 24/25 earnings summary

Executive summary

• Ended FY 2025 with strong double-digit revenue growth and record operating profitability, driven by robust performance across U.S., India, consumer wellness, and international markets.

• Board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, with unmodified audit opinions from Deloitte.

• Q4 FY25 revenues from operations reached Rs. 65,279 mn, up 18% year-over-year, with EBITDA at Rs. 21,255 mn and margin at 32.6%, up 310 bps YoY.

• Net profit excluding exceptional items was Rs. 13,905 mn, up 18% YoY; net cash position improved to Rs. 48,836 mn as of March 31, 2025.

• Strategic focus on differentiated products, innovation pipeline, and expansion in specialty and rare disease segments supported growth.

Financial highlights

• FY 2025 consolidated revenues reached INR 2,232.4 billion, up 19% year-over-year.

• Consolidated net profit for FY25 was Rs. 45,255 million, compared to Rs. 38,595 million in FY24.

• Operating margin improved to 30.4%, up 290 basis points from previous year.

• Q4 revenues were INR 65.3 billion, up 18% year-over-year and 24% sequentially; Q4 EBITDA margin at 32.6%.

• EPS (consolidated, continuing operations) for FY25 was Rs. 44.97, up from Rs. 37.91 in FY24.

Outlook and guidance

• FY 2026 guidance: U.S. business expected to grow in single digits; India and international markets to deliver double-digit growth.

• EBITDA margin for FY 2026 guided at or above 26%, with R&D expenses expected at 8% of sales.

• Continued focus on volume expansion, new product launches, and innovation in branded and generics portfolios.

• Ongoing investments in R&D and pipeline development, including specialty and biosimilar products.

• Dividend payout of Rs. 11 per share recommended for FY25, pending shareholder approval.